503B GLP-1 Injectables
- Home
- 503B Injectables
The FDA has put semaglutide on the Drug Shortages list, providing the opportunity for these GLP-1 injections to be compounded. You can expand your semaglutide offerings by ordering through a national FDA Registered Outsourcing Facility with preferred pricing.
In June 2023, the FDA clarified that 503B Outsourcing Facilities can sell bulk compounded products without patient specific scripts directly to pharmacies to keep in stock. This streamlines the process, ensuring your patients leave satisfied with their prescriptions in-hand, same day.
Streamlined Process for Your Convenience:
Tailored for pharmacies, this ready-to-use product streamlines your operations, freeing you from the complexities of compounding and allowing you to focus on what you do best – providing exceptional customer service.
Quality Assurance:
Compounded in an FDA-Registered Outsourcing Facility under strict USP 800 and cGMP guidelines. Each batch is rigorously inspected under third-party testing for sterility, potency, endotoxins, and particulate matter. And only semaglutide base API is used to create what is essentially a copy with no salt or vitamins added to the formula. Each vial size has also its own NDC Number.
A 180-day BUD (Beyond Use Date) from compounded date for these products frees you from tighter time limitations around 503A compounded semaglutide.
